Developer docs
API playgroundTry for free, no card

Search company profiles

Cagent Vascular

Full company profile

uuid0000969

Namestring
Cagent Vascular
Legal namestring
Cagent Vascular, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cagent Vascular is a privately held, venture-backed medical device company headquartered in Wayne, Pennsylvania, that develops and commercializes the Serranator® PTA Serration Balloon Catheter, the first and only FDA-cleared and CE-marked serrated balloon catheter for endovascular treatment of peripheral artery disease (PAD). The company's proprietary Serration Remodeling Therapy (SRT) embeds stainless-steel serrated strips on a standard angioplasty balloon, applying concentrated point force at low inflation pressures to score along the internal elastic lamina. The stated clinical benefits versus plain balloon angioplasty are predictable lumen gain, reduced recoil, fewer dissections, and lower bailout stent rates across lesion morphologies including above-the-knee (ATK), below-the-knee (BTK), below-the-ankle (pedal), arteriovenous fistula, and iliac applications.

Cagent's product architecture is a single-platform-plus-variants model: the core Serranator catheter (2.5–8.0 mm diameters, 40–120 mm lengths, 0.014"/0.018" guidewire compatible), the Serranator SL-PRO variant for chronic limb-threatening ischemia (CLTI) and pedal disease, and the next-generation Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon remodeling in a disposable catheter. The company has built a portfolio of prospective, core-lab adjudicated clinical studies (PRELUDE, PRELUDE-BTK, Recoil, Pedal, Serranator vs POBA OCT, plus the global REMODEL II pivotal trial for SONIC) and a peer-reviewed publication record, particularly in below-the-ankle interventions. Intellectual property comprises 16 issued US patents and pending foreign applications covering the catheter and method-of-use.

The business model is direct sale of disposable catheters to hospitals, ambulatory surgery centers, and office-based labs through a US field sales force of Sales Territory Managers and Clinical Specialists, with international distribution in the EU and MENA via a partnership with 3comma Medical. Pricing is quote-based and not publicly disclosed. Ancillary revenue support comes from physician education, reimbursement guides, and clinical programs such as the POINT FORCE Observational Registry, which underpin device utilization but are not direct revenue streams. The company has raised approximately $107 million across multiple rounds (2021 exempt offering, 2024 Series C, 2025 growth debt, 2026 Series D), with USVP as the dominant institutional shareholder across all equity rounds. Customers are healthcare providers — primarily interventional cardiologists, vascular surgeons, and endovascular specialists — and named clinical reference sites include Hartford HealthCare, Prisma Health, Baylor Scott & White Health, UT Southwestern, Christiana Care, Clara Maass Medical Center, Columbia University Medical Center, and a vascular centre in Arnsberg, Germany.

Short descriptiontext

Cagent Vascular is a Wayne, Pennsylvania-based private medical device company that develops and sells the Serranator PTA Serration Balloon Catheter, the first FDA-cleared and CE-marked serrated balloon catheter, used by interventional cardiologists and vascular surgeons to treat peripheral artery disease across above-the-knee, below-the-knee, and below-the-ankle vessels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWayne, United States
HQ citystring
Wayne
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral angioplasty devices, balloon catheter technology, vascular intervention devices, intravascular lithotripsy, endovascular medical devices
Industry1 code
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Peripheral Vascular Intervention Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Capital Equipment Sales (Serranator PTA Serration Balloon Catheter)
TypeHardware Sales
Description

Revenue is generated primarily through one-time sale of the Serranator balloon catheter to hospitals, ambulatory surgery centers, and office-based labs. SKUs cover diameters 2.5–8.0 mm and lengths 40–120 mm with GTINs listed in the product ordering table. Sales motion is supported by Sales Territory Managers and Clinical Specialists.

cagentvascular.com
2Reimbursement Support & Clinical Education (Ancillary)
TypeProfessional Services
Description

Cagent publishes reimbursement guides and Instructions for Use (IFU) and runs physician education programs (webinars, case studies, Serranator POINT FORCE Observational Registry) to support adoption and continued usage of its disposable catheter; not a direct revenue stream but underpins device utilization.

cagentvascular.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based pricing; not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Specific unit prices, tier discounts, and contract terms are not listed. Reimbursement guides and IFUs are downloadable from the Resources page.

cagentvascular.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Serranator
Description

Serranator PTA Serration Balloon Catheter — Cagent Vascular's flagship commercial product line for vessel preparation using Serration Remodeling Therapy (SRT) to treat peripheral artery disease (above-the-knee, below-the-knee, and fistulas).

cagentvascular.com
+1 more record
Core offering1 text field

Cagent Vascular develops and sells the Serranator PTA Serration Balloon Catheter, a single-use percutaneous transluminal angioplasty catheter with embedded stainless-steel serrated strips that deliver concentrated point force to remodel the arterial wall at low inflation pressures. The catheter is sold in multiple diameters (2.5–8.0 mm) and lengths for above-the-knee, below-the-knee, below-the-ankle, and arteriovenous fistula interventions in patients with peripheral artery disease. The platform is being extended with the Serranator SL-PRO variant for CLTI and pedal disease, and the Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon-based remodeling.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cagent Vascular's offering is a single-product-platform-plus-variants architecture built around its proprietary Serration Remodeling Therapy (SRT) technology. The core product is the Serranator PTA Serration Balloon Catheter, a serrated angioplasty balloon for treating peripheral artery disease; the SL-PRO is a specialized variant for CLTI and pedal disease, and the Serranator SONIC IVL System is a next-generation device that combines intravascular lithotripsy with the Serranator serrated balloon. Together these named products, the SRT technology platform, and a clinical/education program (registries, studies, case libraries, webinars) form an integrated peripheral-vascular intervention franchise marketed in the U.S. and Europe.

Product and service3 records
1Serranator PTA Serration Balloon Catheter
CategoryPeripheral Vascular Intervention Device
Description

Flagship single-use percutaneous transluminal angioplasty (PTA) balloon catheter featuring embedded stainless-steel serrated strips that deliver concentrated point force along the arterial wall. Available in 2.5–8.0 mm diameters and 40–120 mm lengths, 0.014" and 0.018" guidewire compatible, 6F/7F sheath compatible, 110–150 cm catheter lengths, for above-the-knee, below-the-knee, below-the-ankle, and fistula interventions in patients with peripheral artery disease.

2Serranator SL-PRO
CategoryPeripheral Vascular Intervention Device
Description

Variant of the Serranator PTA Serration Balloon Catheter specifically indicated for chronic limb-threatening ischemia (CLTI) and pedal (below-the-ankle) disease, extending the Serration Remodeling Therapy platform to smaller-vessel, infrapopliteal applications.

3Serranator SONIC Intravascular Lithotripsy (IVL) System
CategoryIntravascular Lithotripsy Device
Description

Next-generation disposable catheter that combines ultrasonic acoustic waves (intravascular lithotripsy) with the serrated balloon-based Serranator remodeling platform to treat complex calcified arterial disease; designed to support the global REMODEL II pivotal trial and a future coronary artery version.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-10
Description

Clinical research partner for the Serranator vs POBA OCT Study, with patient enrollment initiated April 10, 2025. Columbia University Medical Center generates core-lab adjudicated imaging and clinical evidence used to differentiate Serranator from plain balloon angioplasty.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-03
Description

Strategic partnership announced April 3, 2025 to expand international distribution of the Serranator product family across the European Union (EU) and MENA regions. 3comma Medical acts as the regional distributor enabling Cagent Vascular's commercial reach outside the US.

3Serranator SL-PRO Investigator Sites (CLTI and Pedal Disease)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-03
Description

Investigator sites supporting the launch and clinical evaluation of the new Serranator SL-PRO product for critical limb ischemia (CLTI) and pedal disease, announced February 3, 2025.

cagentvascular.com
4Serranator POINT FORCE Observational Registry Investigators
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-28
Description

Multi-physician observational registry initiated January 28, 2025 to collect real-world clinical outcomes on the Serranator across multiple sites and operators, generating evidence to support adoption and reimbursement.

cagentvascular.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Shockwave Medical pioneered intravascular lithotripsy (IVL) for calcified arterial disease and was acquired by Johnson & Johnson for ~$13B. Cagent's Serranator SONIC IVL system directly competes with Shockwave's M5+ and C2+ IVL catheters in peripheral and emerging coronary indications, making it the most analogous peer.

TypeBroad incumbent
Description

Medtronic offers the IN.PACT Admiral drug-coated balloon and a broad peripheral vascular portfolio (including the recent Deep IVL acquisition). It is a key competitor for hospital formulary access and physician share in peripheral artery disease treatment.

3Abbott
TypeBroad incumbent
Description

Abbott's peripheral vascular portfolio includes Stellarex drug-coated balloons and the CSI orbital atherectomy system acquired in 2023. It competes directly with Cagent in vessel preparation and PAD lesion treatment across the same hospital and OBL channels.

TypeBroad incumbent
Description

BD's peripheral intervention portfolio includes the Lutonix drug-coated balloon and atherectomy devices. It competes with Cagent for hospital and office-based lab accounts treating peripheral artery disease and is a broad incumbent in the peripheral vascular space.

TypeBroad incumbent
Description

Philips Volcano and Philips IGT Devices offer peripheral IVUS, Phoenix atherectomy, and related vessel preparation tools. Its broad peripheral portfolio and installed-base imaging franchises make it a meaningful adjacent competitor in vessel preparation.

TypeBroad incumbent
Description

Boston Scientific offers cutting and scoring balloon technology (Flextome, Wolverine) historically used in coronary and peripheral vessels, and a broader peripheral and coronary intervention portfolio. It is a relevant comparable for serration/scoring balloon mechanics and procedural adoption.

TypeDirect peer
Description

Surmodics focuses on peripheral drug-coated balloon technology, including the SurVeil DCB. It competes with Cagent for hospital accounts treating PAD and is a relevant direct peer in peripheral vascular intervention.

TypeDirect peer
Description

AngioDynamics offers peripheral vascular products including the AngioVac system and specialty catheters. As a smaller public competitor focused on vascular interventions, it is comparable in scale and GTM motion to Cagent.

TypeEmerging player
Description

Penumbra's Indigo peripheral thrombectomy system and broader vascular franchise position it as a peripheral interventional peer. While its primary focus is mechanical thrombectomy, it overlaps with Cagent in endovascular peripheral procedures.

TypeEmerging player
Description

Inari Medical (acquired by Stryker in 2025) is a peripheral interventional specialist with FlowTriever and ClotTriever systems for venous thromboembolism. It is comparable as a high-growth, focused peripheral interventional company selling disposables into the same hospital and OBL call points.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cagent Vascular

Peripheral Vascular Intervention Devicescagentvascular.com

Cagent Vascular is a Wayne, Pennsylvania-based private medical device company that develops and sells the Serranator PTA Serration Balloon Catheter, the first FDA-cleared and CE-marked serrated balloon catheter, used by interventional cardiologists and vascular surgeons to treat peripheral artery disease across above-the-knee, below-the-knee, and below-the-ankle vessels.

What Cagent Vascular does

Cagent Vascular is a privately held, venture-backed medical device company headquartered in Wayne, Pennsylvania, that develops and commercializes the Serranator® PTA Serration Balloon Catheter, the first and only FDA-cleared and CE-marked serrated balloon catheter for endovascular treatment of peripheral artery disease (PAD). The company's proprietary Serration Remodeling Therapy (SRT) embeds stainless-steel serrated strips on a standard angioplasty balloon, applying concentrated point force at low inflation pressures to score along the internal elastic lamina. The stated clinical benefits versus plain balloon angioplasty are predictable lumen gain, reduced recoil, fewer dissections, and lower bailout stent rates across lesion morphologies including above-the-knee (ATK), below-the-knee (BTK), below-the-ankle (pedal), arteriovenous fistula, and iliac applications.

Cagent's product architecture is a single-platform-plus-variants model: the core Serranator catheter (2.5–8.0 mm diameters, 40–120 mm lengths, 0.014"/0.018" guidewire compatible), the Serranator SL-PRO variant for chronic limb-threatening ischemia (CLTI) and pedal disease, and the next-generation Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon remodeling in a disposable catheter. The company has built a portfolio of prospective, core-lab adjudicated clinical studies (PRELUDE, PRELUDE-BTK, Recoil, Pedal, Serranator vs POBA OCT, plus the global REMODEL II pivotal trial for SONIC) and a peer-reviewed publication record, particularly in below-the-ankle interventions. Intellectual property comprises 16 issued US patents and pending foreign applications covering the catheter and method-of-use.

The business model is direct sale of disposable catheters to hospitals, ambulatory surgery centers, and office-based labs through a US field sales force of Sales Territory Managers and Clinical Specialists, with international distribution in the EU and MENA via a partnership with 3comma Medical. Pricing is quote-based and not publicly disclosed. Ancillary revenue support comes from physician education, reimbursement guides, and clinical programs such as the POINT FORCE Observational Registry, which underpin device utilization but are not direct revenue streams. The company has raised approximately $107 million across multiple rounds (2021 exempt offering, 2024 Series C, 2025 growth debt, 2026 Series D), with USVP as the dominant institutional shareholder across all equity rounds. Customers are healthcare providers — primarily interventional cardiologists, vascular surgeons, and endovascular specialists — and named clinical reference sites include Hartford HealthCare, Prisma Health, Baylor Scott & White Health, UT Southwestern, Christiana Care, Clara Maass Medical Center, Columbia University Medical Center, and a vascular centre in Arnsberg, Germany.

Cagent Vascular firmographics

Firmographics
Name
Cagent Vascular
Legal name
Cagent Vascular, Inc.
Website
https://cagentvascular.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Cagent Vascular is a Wayne, Pennsylvania-based private medical device company that develops and sells the Serranator PTA Serration Balloon Catheter, the first FDA-cleared and CE-marked serrated balloon catheter, used by interventional cardiologists and vascular surgeons to treat peripheral artery disease across above-the-knee, below-the-knee, and below-the-ankle vessels.
Ownership category
akta.pro rank

Cagent Vascular industry classification

Industry
Product category
Peripheral Vascular Intervention Devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Peripheral angioplasty devices
  • Balloon catheter technology
  • Vascular intervention devices
  • Intravascular lithotripsy
  • Endovascular medical devices

Where Cagent Vascular is headquartered

Location

Headquarters

HQ city
Wayne
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cagent Vascular business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Capital Equipment Sales (Serranator PTA Serration Balloon Catheter): Revenue is generated primarily through one-time sale of the Serranator balloon catheter to hospitals, ambulatory surgery centers, and office-based labs. SKUs cover diameters 2.5–8.0 mm and lengths 40–120 mm with GTINs listed in the product ordering table. Sales motion is supported by Sales Territory Managers and Clinical Specialists.
  2. Reimbursement Support & Clinical Education (Ancillary): Cagent publishes reimbursement guides and Instructions for Use (IFU) and runs physician education programs (webinars, case studies, Serranator POINT FORCE Observational Registry) to support adoption and continued usage of its disposable catheter; not a direct revenue stream but underpins device utilization.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing; not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels11 records

Cagent Vascular product offering

Product offering

Core offering

Cagent Vascular develops and sells the Serranator PTA Serration Balloon Catheter, a single-use percutaneous transluminal angioplasty catheter with embedded stainless-steel serrated strips that deliver concentrated point force to remodel the arterial wall at low inflation pressures. The catheter is sold in multiple diameters (2.5–8.0 mm) and lengths for above-the-knee, below-the-knee, below-the-ankle, and arteriovenous fistula interventions in patients with peripheral artery disease. The platform is being extended with the Serranator SL-PRO variant for CLTI and pedal disease, and the Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon-based remodeling.

Product overview

Cagent Vascular's offering is a single-product-platform-plus-variants architecture built around its proprietary Serration Remodeling Therapy (SRT) technology. The core product is the Serranator PTA Serration Balloon Catheter, a serrated angioplasty balloon for treating peripheral artery disease; the SL-PRO is a specialized variant for CLTI and pedal disease, and the Serranator SONIC IVL System is a next-generation device that combines intravascular lithotripsy with the Serranator serrated balloon. Together these named products, the SRT technology platform, and a clinical/education program (registries, studies, case libraries, webinars) form an integrated peripheral-vascular intervention franchise marketed in the U.S. and Europe.

Differentiator

Problem solved

Functional benefit

Brands

  • Serranator: Serranator PTA Serration Balloon Catheter — Cagent Vascular's flagship commercial product line for vessel preparation using Serration Remodeling Therapy (SRT) to treat peripheral artery disease (above-the-knee, below-the-knee, and fistulas).
  • Serranator SL-PRO

Products and services

  • Serranator PTA Serration Balloon Catheter Flagship single-use percutaneous transluminal angioplasty (PTA) balloon catheter featuring embedded stainless-steel serrated strips that deliver concentrated point force along the arterial wall. Available in 2.5–8.0 mm diameters and 40–120 mm lengths, 0.014" and 0.018" guidewire compatible, 6F/7F sheath compatible, 110–150 cm catheter lengths, for above-the-knee, below-the-knee, below-the-ankle, and fistula interventions in patients with peripheral artery disease.
  • Serranator SL-PRO Variant of the Serranator PTA Serration Balloon Catheter specifically indicated for chronic limb-threatening ischemia (CLTI) and pedal (below-the-ankle) disease, extending the Serration Remodeling Therapy platform to smaller-vessel, infrapopliteal applications.
  • Serranator SONIC Intravascular Lithotripsy (IVL) System Next-generation disposable catheter that combines ultrasonic acoustic waves (intravascular lithotripsy) with the serrated balloon-based Serranator remodeling platform to treat complex calcified arterial disease; designed to support the global REMODEL II pivotal trial and a future coronary artery version.

Companies that use Cagent Vascular

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles1 record

Cagent Vascular technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cagent Vascular partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Columbia University Medical CentercoreStrategic or Co-development Partner · 10 April 2025Clinical research partner for the Serranator vs POBA OCT Study, with patient enrollment initiated April 10, 2025. Columbia University Medical Center generates core-lab adjudicated imaging and clinical evidence used to differentiate Serranator from plain balloon angioplasty.
  • 3comma MedicalflagshipChannel Partner/ Reseller/ Distributor · 3 April 2025Strategic partnership announced April 3, 2025 to expand international distribution of the Serranator product family across the European Union (EU) and MENA regions. 3comma Medical acts as the regional distributor enabling Cagent Vascular's commercial reach outside the US.
  • Serranator SL-PRO Investigator Sites (CLTI and Pedal Disease)coreStrategic or Co-development Partner · 3 February 2025Investigator sites supporting the launch and clinical evaluation of the new Serranator SL-PRO product for critical limb ischemia (CLTI) and pedal disease, announced February 3, 2025.
  • Serranator POINT FORCE Observational Registry InvestigatorscoreStrategic or Co-development Partner · 28 January 2025Multi-physician observational registry initiated January 28, 2025 to collect real-world clinical outcomes on the Serranator across multiple sites and operators, generating evidence to support adoption and reimbursement.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Cagent Vascular competitors and assessment

Company assessment

Direct peers

  • Shockwave Medical: Shockwave Medical pioneered intravascular lithotripsy (IVL) for calcified arterial disease and was acquired by Johnson & Johnson for ~$13B. Cagent's Serranator SONIC IVL system directly competes with Shockwave's M5+ and C2+ IVL catheters in peripheral and emerging coronary indications, making it the most analogous peer.
  • Surmodics: Surmodics focuses on peripheral drug-coated balloon technology, including the SurVeil DCB. It competes with Cagent for hospital accounts treating PAD and is a relevant direct peer in peripheral vascular intervention.
  • AngioDynamics: AngioDynamics offers peripheral vascular products including the AngioVac system and specialty catheters. As a smaller public competitor focused on vascular interventions, it is comparable in scale and GTM motion to Cagent.

Broad incumbents

  • Medtronic: Medtronic offers the IN.PACT Admiral drug-coated balloon and a broad peripheral vascular portfolio (including the recent Deep IVL acquisition). It is a key competitor for hospital formulary access and physician share in peripheral artery disease treatment.
  • Abbott: Abbott's peripheral vascular portfolio includes Stellarex drug-coated balloons and the CSI orbital atherectomy system acquired in 2023. It competes directly with Cagent in vessel preparation and PAD lesion treatment across the same hospital and OBL channels.
  • BD (Becton Dickinson): BD's peripheral intervention portfolio includes the Lutonix drug-coated balloon and atherectomy devices. It competes with Cagent for hospital and office-based lab accounts treating peripheral artery disease and is a broad incumbent in the peripheral vascular space.
  • Philips: Philips Volcano and Philips IGT Devices offer peripheral IVUS, Phoenix atherectomy, and related vessel preparation tools. Its broad peripheral portfolio and installed-base imaging franchises make it a meaningful adjacent competitor in vessel preparation.
  • Boston Scientific: Boston Scientific offers cutting and scoring balloon technology (Flextome, Wolverine) historically used in coronary and peripheral vessels, and a broader peripheral and coronary intervention portfolio. It is a relevant comparable for serration/scoring balloon mechanics and procedural adoption.

Emerging players

  • Penumbra: Penumbra's Indigo peripheral thrombectomy system and broader vascular franchise position it as a peripheral interventional peer. While its primary focus is mechanical thrombectomy, it overlaps with Cagent in endovascular peripheral procedures.
  • Inari Medical (Stryker): Inari Medical (acquired by Stryker in 2025) is a peripheral interventional specialist with FlowTriever and ClotTriever systems for venous thromboembolism. It is comparable as a high-growth, focused peripheral interventional company selling disposables into the same hospital and OBL call points.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cagent Vascular social profiles

Digital presence

Cagent Vascular compliance and trust

Trust signal

Compliance3 records

Cagent Vascular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cagent Vascular leadership team

Management profile

Number of profiles

Profiles8 records

Cagent Vascular funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cagent Vascular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cagent Vascular

What does Cagent Vascular do?

Cagent Vascular develops and sells the Serranator PTA Serration Balloon Catheter, a single-use percutaneous transluminal angioplasty catheter with embedded stainless-steel serrated strips that deliver concentrated point force to remodel the arterial wall at low inflation pressures. The catheter is sold in multiple diameters (2.5–8.0 mm) and lengths for above-the-knee, below-the-knee, below-the-ankle, and arteriovenous fistula interventions in patients with peripheral artery disease. The platform is being extended with the Serranator SL-PRO variant for CLTI and pedal disease, and the Serranator SONIC intravascular lithotripsy (IVL) system that combines ultrasonic acoustic waves with serrated balloon-based remodeling.

Is Cagent Vascular a public or private company?

Cagent Vascular is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cagent Vascular founded?

Cagent Vascular was founded in 2014. It employs 101 to 250 people.

Where is Cagent Vascular based?

Cagent Vascular is headquartered in Wayne, United States, in the North America region.

How does Cagent Vascular make money?

Two revenue lines are on record. Capital Equipment Sales (Serranator PTA Serration Balloon Catheter) is the primary driver. The others are reimbursement Support & Clinical Education (Ancillary).

Who are Cagent Vascular's main competitors?

Direct peers on record are Shockwave Medical, Surmodics and AngioDynamics. Broad incumbents are Medtronic, Abbott, BD (Becton Dickinson), Philips and Boston Scientific. Emerging players are Penumbra and Inari Medical (Stryker).

Does Cagent Vascular have an API?

No public API is recorded for Cagent Vascular.

What industry is Cagent Vascular in?

Cagent Vascular's product category is Peripheral Vascular Intervention Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device and Diagnostic industryIVL Market Explodes: 4 Companies Announce Breakthroughs In A DaySeveral companies announced significant advancements in the Intravascular Lithotripsy (IVL) market, highlighting its rapid growth and competitive landscape. Key developments include Cagent Vascular's successful first-in-human use of the Serranator SONIC IVL System, Boston Scientific's positive FRACTURE trial results for its SEISMIQ 4CE device, and Stryker's new subsidiary Amplitude Vascular Systems launching its Pulse IVL System study. Additionally, FastWave Medical received four new international patents for its IVL platforms, signaling its expanding innovation in this sector.VenturecapitalCagent Vascular Reaches Key Milestones and Secures $41 Million in Series D FundingCagent Vascular closed a $41 million Series D financing round to support its global REMODEL II pivotal trial and commercial launch of the Serranator SONIC IVL System. The company also achieved key milestones with the system.VC News DailyCagent Vascular Inks $41M Series D RoundCagent Vascular announced the closing of a $41 million Series D financing round co-led by U.S. Venture Partners and Astoria Health Investors. The funding will support the global REMODEL II pivotal trial and commercial launch of the Serranator® SONIC Intravascular Lithotripsy System, as well as development of the company's coronary artery platform.VascularnewsCagent Vascular reports first human use of Serranator Sonic IVL system, closes oversubscribed US$41 million Series D financingCagent Vascular successfully completed the first human-use cases with its Serranator Sonic intravascular lithotripsy (IVL) system and closed a US$41 million Series D financing round. This financing will support the global REMODEL II trial and the commercial launch of the system, which is expected to target a larger share of the peripheral and coronary arterial markets. The first procedures took place in Uzbekistan as part of a multicenter safety and performance study.Medical Device NetworkCagent Vascular raises $41m for dual-modality IVL platform advancementCagent Vascular has raised $41 million in Series D financing co-led by US Venture Partners and Astoria Health Investors to advance its dual-modality Serranator SONIC intravascular lithotripsy platform. The company completed the first-in-human use cases for the device in Uzbekistan as part of the REMODEL I study, with funds designated for the pivotal REMODEL II trial and commercial activities. This development positions Cagent to compete more aggressively in the IVL market, which has seen significant consolidation including Johnson & Johnson's acquisition of Shockwave Medical.citybizCagent Vascular Raises $41M After First Human Use of New IVL PlatformCagent Vascular has completed first human procedures using its Serranator SONIC intravascular lithotripsy system while closing an oversubscribed $41 million Series D financing round co-led by U.S. Venture Partners and Astoria Health Investors. The funding will support the global REMODEL II pivotal trial, commercialization of the combined IVL and serrated balloon platform, and development of a coronary artery version. The platform differentiates itself by combining ultrasonic acoustic waves with serrated balloon-based remodeling in a fully disposable system designed to treat complex calcified arterial disease.Pulse 2.0Cagent Vascular: $41 Million Series D Raised Following First Human Use Of Serranator SONIC IVL SystemCagent Vascular successfully completed its first human-use cases with the Serranator SONIC IVL System and raised $41 million in Series D funding, supporting clinical advancement and commercialization. The platform aims to improve treatment of calcified arterial disease and will be used in a pivotal trial and global rollout.MassDeviceCagent Vascular reports first-in-human IVL cases, closes $41M Series DCagent Vascular announced the first human use of its Serranator Sonic IVL system in Uzbekistan and closed a $41 million Series D funding round. The company plans to utilize the proceeds to fund a global pivotal trial and support the commercial launch of the device, which combines serration remodeling therapy with sonic lithotripsy. This development positions Cagent as a new entrant in the intravascular lithotripsy market led by Johnson & Johnson.Venture Capital Access OnlineCagent Vascular Reports First Human Use of Serranator® SONIC IVL System and Closes Oversubscribed $41M Series D FinancingCagent Vascular completed first human-use cases of its Serranator SONIC IVL system in Uzbekistan and closed a $41 million Series D financing round. The system combines SRT and ultrasonic lithotripsy, targeting a $17 billion peripheral and coronary arterial market. Proceeds will fund the global REMODEL II trial and commercial launch.openPR.comLeading Industry Participants Enhancing Their Presence in the PTA Balloon Catheter MarketThe Business Research Company released a market analysis report projecting the PTA balloon catheter market to reach $4.31 billion by 2030, growing at a 10.8% CAGR, driven by rising adoption of minimally invasive vascular treatments and increasing prevalence of peripheral artery disease. In November 2023, OrbusNeich Medical Group Holdings Limited, a Hong Kong-based medical device firm, acquired Eucatech AG, a Germany-based cardiovascular technology company, for EUR 2.4 million, strengthening its portfolio with CE-marked paclitaxel-coated PTA balloons. In February 2025, US-based Cagent Vascular launched the Serranator SL Pro, a next-generation serration-enhanced PTA balloon catheter for treating chronic limb-threatening ischemia and pedal artery disease.